Companies › Shanghai EpimAb Biotherapeutics
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bafisontamab (EMB-01) Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | MET, EGFR | Phase 2 | Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal Cancer | Dec 2027 |
| EMB-07 Bispecific antibody targeting CD3 and ROR1 | CD3, ROR1 | Phase 1 | Combination Therapy | Jun 2028 |
| EMB-15 Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager | ALPP, ALPG, CD3 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07314294 | Bafisontamab (EMB-01) | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2027 |
| NCT07649655 | Bafisontamab (EMB-01) | Phase 1 | Unresectable/Metastatic Colorectal Cancer | Oncology | Mar 2028 |
| NCT07432022 | EMB-07 | Phase 1 | Combination Therapy | Oncology | Jun 2028 |
| NCT07607054 | EMB-15 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | May 2029 |
AstraZeneca Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Shanghai Henlius Biotech Betta Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Pierre Fabre Medicament Allist Pharmaceuticals Dizal Pharmaceuticals
iTeos Therapeutics SUNHO(China)BioPharmaceutical Takara Bio OBI Pharma ALX Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.